Establishment and characterization of a cell line from human circulating colon cancer cells.

Circulating tumor cells (CTC) in blood are promising new biomarkers potentially useful for prognostic prediction and monitoring of therapies in patients with solid tumors including colon cancer. Moreover, CTC research opens a new avenue for understanding the biology of metastasis in patients with cancer. However, an in-depth investigation of CTCs is hampered by the very low number of these cells, especially in the blood of patients with colorectal cancer. Thus, the establishment of cell cultures and permanent cell lines from CTCs has become the most challenging task over the past year. Here, we describe, for the first time, the establishment of cell cultures and a permanent cell line from CTCs of one patient with colon cancer. The cell line designated CTC-MCC-41 has been cultured for more than one year, and the cells have been characterized at the genome, transcriptome, proteome, and secretome levels. This thorough analysis showed that CTC-MCC-41 cells resemble characteristics of the original tumor cells in the patient with colon cancer and display a stable phenotype characterized by an intermediate epithelial/mesenchymal phenotype, stem cell-like properties, and an osteomimetic signature, indicating a bone marrow origin. Functional studies showed that CTC-MCC-41 cells induced rapidly in vitro endothelial cell tube formation and in vivo tumors after xenografting in immunodeficient mice. The establishment of this first colon cancer CTC line allows now a wealth of functional studies on the biology of CTCs as well as in vitro and in vivo drug testing.

[1]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[2]  K. Pantel,et al.  Real-time liquid biopsy in cancer patients: fact or fiction? , 2013, Cancer research.

[3]  P. Atadja,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[4]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[5]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.

[7]  Wei Yin,et al.  The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis , 2013, Science Translational Medicine.

[8]  B. Vincenzi,et al.  MicroRNAs and Bone Metastasis: A New Challenge , 2014, Molecules.

[9]  Lei Du,et al.  CD44 is of Functional Importance for Colorectal Cancer Stem Cells , 2008, Clinical Cancer Research.

[10]  T. Fehm,et al.  Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. , 2014, Clinical chemistry.

[11]  Tao Wang,et al.  Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer , 2012, Clinical Cancer Research.

[12]  T. Price,et al.  Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Bodmer,et al.  Cancer stem cells from colorectal cancer-derived cell lines , 2010, Proceedings of the National Academy of Sciences.

[14]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.

[15]  J. Rich,et al.  Hypoxia inducible factors in cancer stem cells , 2010, British Journal of Cancer.

[16]  Lei Du,et al.  CD 44 is of Functional Importance for Colorectal Cancer Stem Cells , 2008 .

[17]  V. Castronovo,et al.  A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. , 2007, Cancer research.

[18]  Klaus Pantel,et al.  Circulating tumour cells in cancer patients: challenges and perspectives. , 2010, Trends in molecular medicine.

[19]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[21]  Houjie Liang,et al.  Highly enriched CD133+CD44+ stem-like cells with CD133+CD44high metastatic subset in HCT116 colon cancer cells , 2011, Clinical & Experimental Metastasis.

[22]  Tim Holland-Letz,et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.

[23]  K. Pantel,et al.  Circulating tumor cells and circulating tumor DNA. , 2012, Annual review of medicine.

[24]  L. Suva,et al.  Osteoprotegrin and the bone homing and colonization potential of breast cancer cells , 2008, Journal of cellular biochemistry.

[25]  T. Maudelonde,et al.  Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. , 2005, Clinical chemistry.

[26]  K. Pantel,et al.  Capture of viable circulating tumor cells in the liver of colorectal cancer patients. , 2013, Clinical chemistry.

[27]  C. Alix-Panabières EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. , 2012, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[28]  C. Moskaluk,et al.  CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. , 2005, Human pathology.

[29]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[30]  E. Elkord,et al.  Significance of CD44 and CD24 as Cancer Stem Cell Markers: An Enduring Ambiguity , 2012, Clinical & developmental immunology.

[31]  J. Köllermann,et al.  Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.

[33]  M. Slijper,et al.  Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer , 2009, Breast Cancer Research.

[34]  Lei Wang,et al.  Clinical outcomes after surgical resection of colorectal cancer in 1,294 patients. , 2011, Hepato-gastroenterology.

[35]  K. Pantel,et al.  Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. , 1999, Cancer research.